Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA has evaluated the content of Amgen's complete response submission for Prolia (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.
Subscribe to our email newsletter
Earlier, in October 2009, the division of reproductive and urologic products at FDA has issued a complete response letter for the biologic license application (BLA) for Prolia in the treatment and prevention of postmenopausal osteoporosis.
The letter requested several items, including further information on the design of Amgen’s previously submitted post-marketing surveillance program. The letter did not require additional pre-marketing clinical trials to complete the review of the treatment indication.
The FDA has also requested all updated safety data related to Prolia. Amgen has submitted the requested information for the treatment indication in late January 2010.
Amgen continues to work with the FDA to determine appropriate next steps regarding its indications for Prolia in the prevention of postmenopausal osteoporosis, as well as in the treatment and prevention of bone loss due to hormone ablation in breast and prostate cancer patients.